The US Food and Drug Administration (FDA) has released draft guidance on how sponsors can utilize next-generation sequencing ...
A new class of beta blockers designed to activate only when struck by specific wavelengths of light could allow doctors to switch drug activity on and off inside targeted tissues, potentially ...
The document outlines the non-clinical sequencing and bioinformatics data sponsors need to submit as part of INDs and BLAs for gene-editing therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results